Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
37 participants
OBSERVATIONAL
2020-02-27
2020-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There are more and more cases of eligible patients to transplant with an antecedent of melanoma. There is no guideline yet.
Main objective is survival time without melanoma recurrence in this population to do guideline of time limit or not between melanoma and transplantation by stage.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma
NCT05527795
Variations of Immune Infiltrate and Cell Plasticity Markers in Treated Metastatic Melanoma Patients
NCT05029791
Tracing Dissemination of Melanoma Cells in Healthy Tissues
NCT02854124
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
NCT01709162
Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary
NCT02828202
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
patient with melanoma pre transplantation
survival time without melanoma recurrence
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Not opposite to participate
Exclusion Criteria
* patient under Guardianship
* patient not affiliated with a health system
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emilie DUCROUX, MD
Role: PRINCIPAL_INVESTIGATOR
Service de Dermatologie, Hôpital Edouard Herriot, Lyon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
service de dermatologie - hopital Edouard Herriot
Lyon, Rhone, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
69HCL19_0636
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.